High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999 - 2006

Pramil Cheriyath, Venkata Subhash Gorrepati, Ian Peters, Vinod Nookala, Megan E Murphy, Nadine Srouji, Daniel Fischman

Abstract

Background: Diabetes Mellitus (DM) is a rampantly growing epidemic in the United States, affecting nearly 10% of the adult population. Studies have shown that higher levels of Total Bilirubin (TBili) convey a protective effect with regard to cardiovascular risk. In this study, we will examine the relationship between TBili level and prevalence of DM to discern whether a similar relationship exists.

Methods: The National Health and Nutrition Examination Survey (NHANES) is a comprehensive survey performed regularly to evaluate the overall health and nutrition status of the United States population. For the purpose of this study, we combined NHANES data collected between 1999 and 2006. Totally 15,876 eligible participants were selected after excluding all patients younger than twenty years, those with a history of abnormal liver function tests, or those who disclosed a history of liver disease. The data collected on these individuals was adjusted for demographic characteristics, as well as risk factors for DM, and was analyzed via multivariate logistic regression, using SAS proc survey methodology.

Results: After age adjustment, increased TBili was associated with 26% reduction in diabetes risk (OR 0.74, 95% CI 0.64 - 0.88). Multivariate analysis, adjusting for all diabetes risk factors assessed, confirmed this association (OR 0.80, 95% CI 0.67 - 0.95).

Conclusions: Our results show that a higher level of serum TBili is associated with odds of having a lower incidence of DM. This finding supports the hypothesis that the antioxidant nature of TBili, demonstrating a protective effect with regard to the risk of stroke, atherosclerosis, and vasculitis in prior research, also extends to DM risk. Furthermore, research has shown that higher levels of TBili increase glucose mobilization into the cells, leading to more efficient, biologic glucose utilization. There is no doubt that the beneficial effect of TBili is multifactorial; thus further investigation is warranted.

Keywords: Bilirubin; Diabetes; Antioxidant; Protective

Introduction

Diabetes Mellitus has become an epidemic throughout the world. Prevalence data, collected in 2007, indicate that 7.8% of the population have been diagnosed with this disease [1]. From a fiscal standpoint, the diagnosis of Diabetes Mellitus is associated with a two-fold rise in medical cost, equaling approximately $116 billion dollars in direct expenditures and $58 million in indirect expenditures, in the United States (US) [1]. Given this disease’s dramatic impact on the physical and financial health of the US population, disease prevention has taken on paramount importance. With this focus in mind, research activity has focused on finding physiologic factors that decrease a person’s risk of developing Diabetes Mellitus.

Bilirubin has been conjectured to be one such factor. There is a growing body of literature which shows that higher Total Bilirubin levels (TBili) are protective against cardiovascular disease, Stroke and Peripheral Arterial Disease [2-7]. Studies suggest that an increased expression of Heme Oxygenase, an enzyme used to break down the hemoglobin into bilirubin, is associated with enhanced insulin sensitivity and glucose metabolism, thus resulting in greater rates of rat model euglycemia [8, 9]. Furthermore, the antioxidant properties of TBili have been postulated to reverse oxidative damage associated with a hyperglycemic state [10]. Consequently, we have undertaken this population-based study to assess whether higher levels of TBili, within the physiologically normal range, convey a decreased risk of Diabetes Mellitus in the US population.

Manuscript accepted for publication August 11, 2010

aPinnacle Health/ Harrisburg Hospital, Harrisburg, PA, USA
bPhiladelphia College of Osteopathic Medicine, Philadelphia, PA, USA
cCorresponding author: Pinnacle Health/ Harrisburg Hospital, 205 S Front Street, Harrisburg, PA 17104, USA
Email: pcheriyath@pinnaclehealth.org
doi:10.4021/jocmr425w
Materials and Methods

The National Health and Nutrition Examination Survey (NHANES) is a nation-wide survey performed jointly by the National Center for Health Statistics and the Center for Disease Control and Prevention (CDC), on a representative sample of the United States (US) population. This sample is chosen using a stratified, multistage probability cluster sampling design of the non-institutionalized, non-military US population [11]. Components of this survey include questionnaires about demographics and health status, general medical examinations, as well as laboratory tests of varied bodily fluids. The physical examination component of NHANES consists of medical, dental, AND anthropometric measurements collected by trained personnel [12].

For the purpose of our study, we examined NHANES data collected between 1999 and 2006. Exclusion criteria in our protocol removed all data for NHANES participants who were younger than twenty years-of-age, who reported a history of liver disease, who had abnormal liver function studies, or who had missing data values. Of 41,474 participants who had data collected during our seven-year period-of-interest, 15,876 did not meet any of the exclusion criteria. Based on previous studies we stratified TBili into two groups. One had the TBili level of less than 10 micromol/L and the other had a level of greater than or equal to 10 micromol/L [2, 23].

Laboratory methods

To measure total Bilirubin, NHANES used the LX20 process which utilizes a timed endpoint Diazo method. The basis of this method is formation of Azobilrubin from a reaction with a Diazo reagent. The change in the absorbance level of the reagent is measured, as this value is directly proportional to the concentration of Bilirubin. Fasting blood sugar was measured using Roche/Hitachi 911 instrument (Roche Diagnostics, Indianapolis) on early morning serum sample, for which subjects were asked to fast for nine hours. [11].

Case definition

Case definition of Diabetes Mellitus was based on fasting blood sugar value of not less than 126 mg/dl (7.0 mmol/L) and the participant’s response to the following questions: (1) ‘Other than during pregnancy, have you ever been told by a doctor or other health professional that you have diabetes or sugar diabetes?’; (2) ‘Are you taking insulin now?’; (3) ‘Are you taking any pills to decrease your blood sugar?’.

Definition of covariables

The NHANES questionnaire section was used for the characterization of age, sex, race, tobacco use pattern, alcohol use, highest level of education achieved, and marital status.
of 5.31.

The demographic variables of the two groups were compared by age adjusted prevalence (Table 1). A greater proportion of men were found to have a serum TBili level above 10 micromol/L. For individuals who had Diabetes Mellitus, 70.45% (SE = 0.86) had a TBili level of 10 micromol/L. Furthermore, a statistically-significant, unadjusted association between higher TBili level and Diabetes did exist (OR: 0.74, 95% CI: 0.64 - 0.88). The relationship remained significant, after adjusting for age, sex, race, married status, education, BMI and smoking (OR: 0.80, 95% CI: 0.67 - 0.95) (Fig. 2 and 3).

Discussion

Our study supports the notion that people with high TBili have lesser odds of prevalence of Diabetes Mellitus (DMI and DMII). This is in keeping with previously reported studies which have shown higher TBili levels to be protective against Coronary Artery Disease, Stroke and Peripheral Vascular Disease [2-7].

Bilirubin has been regarded as a powerful endogenous anti-oxidant and anti-inflammatory agent [14-18]. Thus, it stands to reason that higher TBili levels may be protective against the autoimmune, inflammation-related pathology of type 1 diabetes and oxidative physiologic stress associated with development of type 2 diabetes [19]. Current research also suggests that physiological levels of TBili block the production of various free radicals that might hinder the inhibitory responses of the cell to take up the high glucose [20]. Furthermore, it is shown to prevent the vascular endothelial activation from the oxidative stress in the vessels [21, 22].

In addition, rat model studies of DM II have shown that...
increased expression of Heme Oxygenase-1, the enzyme responsible for conversion of Hemoglobin to Bilirubin, is associated with enhanced insulin sensitivity and glucose metabolism resulting in greater rates of rat model euglycemia. Moreover, Hemin, an activator of the Heme Oxygenase system, has been found to increase the expression of GLUT-4 receptors and Adiponectin, a hormone which increases insulin sensitivity [20]. Similar to TBili, and in light of its anti-inflammatory properties, higher Adiponectin levels have been associated with lower DM prevalence. However, unlike Adiponectin since TBili is a commonly measured laboratory value, measuring TBili levels would offer a cost-effective method of DM risk stratification.

This study follows a complex sampling with the provision of the weights, which makes it more realistic to project on to the United States population. The amalgamation of four large cross sectional surveys done on the representative population of the United States from 1999 to 2006 translated this study high volume population based study. So we got a fair amount of population who have diabetes and who didn’t. The stratification of total bilirubin into 2 groups, one having a TBili level of less than 10 micromol/L and the other having the TBili level of greater than or equal to 10 millimol/L is based on previous study which showed that a level of TBili equal to or above 10 millimol/L is cardio protective [23].

Another interesting observation is that there is a greater...
distribution of population in the higher TBili group which had the bilirubin greater or equal to 10 micromol/L, which was nearly consistent in all demographic groups. Needless to say also is most of the population distribution in the latter group (≥ 10 micromol/L) with respect to prevalence of diabetes and prevalence of ‘no diabetes’ (66.1% vs 33.8% of diabetes group and 70.5% vs 29.5% of ‘no diabetes’ group).

Our use of population-adjusted data from a national survey, using predetermined definition is not without its limitations. One major limitation to this study is that the definition of Diabetes Mellitus is predicated on subject recollection and self reported diagnosis, thus introducing a component of recall bias. In order to compensate for this, we have added fasting blood sugar measurements into our study’s definition of Diabetes Mellitus.

For similar reasons, our study is limited in its ability to determine whether the protective effects of TBili are limited to only one form of Diabetes Mellitus, or whether the protective effect influences the incidence and prevalence of both DM type1 and type 2. Also, the cross sectional nature of the data derived from NHAHES’s methodology hinders determination of a temporal association or the cause-and-effect between TBili and development of DM type 1 or type 2. The lack of fractionation of TBili also limits our ability to determine whether it is the indirect fraction, the direct fraction, or a combined effect of the varied fractions of TBili, which convey the protective effect we described in this study [24].

In conclusion, there appears to be a beneficial effect of TBili on Diabetes. Further investigation is warranted in order to delineate whether this protective phenomenon extends to all forms of Diabetes Mellitus, whether it is conveyed by both Indirect and Direct Bilirubin, and what avenues are available to therapeutically raise an at-risk patient’s bilirubin levels for optimal protection from this dreaded disease.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2008.Revived from http://diabetes.niddk.nih.gov/DMPUBS/statistics/ on 6/11/2009.
2. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40(1):18-23.
3. Perlstein TS, Pande RL, Creager MA, Weuve J, Becksman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121(9):781-788 e781.
4. Perlstein TS, Pande RL, Becksman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008;28(1):166-172.
5. Vitek L. Impact of serum bilirubin on human diseases. Pediatrics 2005;115(5):1411-1412.
6. Lin JP, O’Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006;114(14):1476-1481.
7. Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 2002;21(1):44-52.
8. Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing pathways. Endocrinology 2009;150(5):2098-2108.
9. Ndisang JF, Jadhav A. Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes. Am J Physiol Endocrinol Metab 2009;296(4):E829-841.
10. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2009;296(5):E1029-1041.
11. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2009][http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm].
12. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Questionnaire (or Examination Protocol, or Laboratory Protocol). Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2009][http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm].
13. Centers for Disease Control and Prevention (CDC) [2009] retrieved from http://www.cdc.gov/healthy-weight/assessing/bmi/adult_BMI/index.html on 06/18/2009.
14. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987;235(4792):1043-1046.
15. Hammerman C, Goldstein R, Kaplan M, Eran M, Goldschmidt D, Eidelman AI, Gartner LM. Bilirubin in the premature: toxic waste or natural defense? Clin Chem 1998;44(12):2551-2553.
16. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-
inflammatory effect of interleukin-10 in mice. Nat Med 2002;8(3):240-246.
17. Arai T, Yoshikai Y, Kamiya J, Nagino M, Uesaka K, Yuasa N, Oda K, et al. Bilirubin impairs bactericidal activity of neutrophils through an antioxidant mechanism in vitro. J Surg Res 2001;96(1):107-113.
18. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 2004;66(4):773-779.
19. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003;81(8):455-470.
20. Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008;31(8):1615-1620.
21. Rodella L, Lamon BD, Rezzani R, Sangras B, Goodman AI, Falck JR, Abraham NG. Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radic Biol Med 2006;40(12):2198-2205.
22. Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsu-moto H, Kohro T, Itabe H, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol 2005;25(1):155-160.
23. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003;228(5):568-571.
24. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996;51(6):859-862.